CagriSema Explained: Semaglutide Plus Cagrilintide

CagriSema is Novo Nordisk's once-weekly injectable that combines glp-1/weight-loss-on-semaglutide">semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analog, in a single pen. It pairs two different appetite-regulating hormones in the hope of producing more weight loss than either alone, and it was tested in the large REDEFINE phase 3 program for obesity. As of this writing it is filed and under regulatory review, but it is NOT yet FDA-approved, so a clinician cannot prescribe CagriSema for weight management today. This guide explains what each half of the combination does, what the REDEFINE trials actually showed, why the early readouts were seen as strong yet slightly below the highest expectations, and how CagriSema stacks up against semaglutide on its own and against tirzepatide.

The short version is that CagriSema is a genuine attempt to move past single-hormone therapy by recruiting a second satiety pathway. Whether it becomes a meaningful option depends on regulators finishing their review and on how its real-world results compare to drugs that are already on pharmacy shelves. We are deliberate about that distinction throughout, because in this field the gap between promising trial data and an approved prescription is wide.

What CagriSema is, in plain terms

CagriSema is a fixed combination of two molecules delivered together once a week by subcutaneous injection. The first molecule, semaglutide, is the same GLP-1 receptor agonist already familiar from Ozempic and Wegovy. The second, cagrilintide, is an engineered, long-acting version of amylin, a hormone the body releases from the pancreas alongside insulin after a meal. Neither component is new on its own. Semaglutide has years of data behind it, and cagrilintide had been studied as a standalone weight-loss agent. CagriSema is the idea of putting them in one pen and dosing them together.

The logic is straightforward. GLP-1 and amylin reduce appetite through overlapping but distinct routes in the brain and gut. If you engage both at once, the theory goes, you get an additive or even synergistic effect on how full people feel and how much they eat. That is the same broad strategy behind other combination drugs in the class, except CagriSema reaches for amylin rather than a second incretin hormone.

What each component does

To understand why anyone would combine these two, it helps to look at each on its own.

Semaglutide: the GLP-1 half

Semaglutide mimics glucagon-like peptide-1, a gut hormone released after eating. It slows how fast the stomach empties, acts on appetite centers in the brain to reduce hunger and food intake, and improves blood-sugar control by prompting insulin release when glucose is high. In its pivotal obesity trial, once-weekly semaglutide produced mean weight loss of roughly 15%. The mechanism is laid out in detail in our explainer on what GLP-1 is and in the deeper dive on how semaglutide works. For CagriSema, semaglutide is the proven backbone the combination builds on.

Cagrilintide: the amylin half

Amylin is co-secreted with insulin and contributes to fullness in its own right. It slows gastric emptying, signals satiety to the brain, and helps blunt the post-meal rise in glucagon. Native amylin is short-lived and clumps together, which makes it impractical as a drug, so cagrilintide is a re-engineered analog designed to stay active for about a week. On its own, cagrilintide produced meaningful weight loss in earlier studies. The point of combining it with semaglutide is that amylin works through a separate pathway from GLP-1, so the two should add to each other rather than simply doing the same job twice.

Why combine GLP-1 and amylin?

Appetite is not controlled by a single switch. The body uses a network of hormones to coordinate hunger, fullness, and energy balance, and no one drug touches all of them. GLP-1 agonists are powerful, but a meaningful share of people respond only partially, and weight loss tends to plateau as the body adapts. The rationale for adding amylin is to hit a second, independent satiety signal so the combined effect on appetite is stronger and harder to fully adapt around.

This is the conceptual cousin of what tirzepatide does by pairing GLP-1 with GIP, except CagriSema reaches outside the incretin family entirely. Amylin is a different hormone with a different receptor system, which is exactly why it is interesting: it could help people who do not get the full benefit from a GLP-1 alone. The broader principle, that activating more than one appetite pathway tends to outperform a single one, is the same thread running through the whole modern pipeline, including the triple agonists covered in our roundup of the newest GLP-1 drugs. The underlying gut-hormone biology that all of these agents are built on is unpacked by Drucker's work on the mechanisms of GLP-1.

The REDEFINE program: what the trials showed

CagriSema was tested in REDEFINE, Novo Nordisk's phase 3 clinical program in obesity. The headline result was substantial mean weight loss, in the same broad neighborhood as the most effective approved drugs, which confirmed that the combination is genuinely potent. By any historical standard, the numbers are large.

There is an important nuance, though, and being honest about it matters. When the early REDEFINE readouts arrived, they were widely viewed as below the highest expectations that had built up around the drug. Forecasts had floated weight loss approaching or exceeding the strongest figures in the field, and the actual result, while strong and landing in roughly the low-to-mid 20% range at the high end, did not clear that very high bar by a wide margin. Part of the story was trial design: many participants did not reach or stay on the top dose, which pulled down the average. The takeaway is not that CagriSema disappointed in absolute terms. It is that expectations had been set unusually high, and the data came in strong rather than spectacular.

Attribute	CagriSema
Components	Semaglutide (GLP-1 agonist) + cagrilintide (amylin analog)
Route / frequency	Subcutaneous injection, once weekly
Manufacturer	Novo Nordisk
Phase 3 program	REDEFINE (obesity)
Weight loss (high level)	Substantial; roughly low-to-mid 20% range at the top, viewed as below the very highest expectations
Regulatory status	Filed and under review; NOT yet FDA-approved as of mid-2026

How CagriSema compares to semaglutide alone

The most direct question is whether adding amylin beats semaglutide by itself. On the trial evidence, CagriSema did produce more average weight loss than semaglutide alone, which is the result the combination was designed to deliver and the basic justification for using two molecules instead of one. So the added cagrilintide does appear to do real work.

The practical caveats are the ones that apply to any drug in this class. The extra benefit comes with the side-effect profile of two appetite-suppressing agents stacked together, so gastrointestinal effects such as nausea remain the main tolerability issue, and dose escalation has to be managed carefully. And like every GLP-1-based therapy, the weight loss persists only while treatment continues. If you want to see how semaglutide alone performs across different drugs and doses, our GLP-1 weight-loss results by drug breakdown puts the numbers side by side.

How CagriSema compares to tirzepatide

Tirzepatide is the natural benchmark because it is the current high-water mark among approved obesity drugs, with mean weight loss around 21% in its pivotal trial, and because it too is a combination, pairing GLP-1 with GIP. That makes for a clean contrast: two different two-hormone strategies, one already approved and one still under review.

On the available data, CagriSema lands in a broadly similar range to tirzepatide rather than clearly surpassing it, which is a large part of why the early readouts felt underwhelming relative to the hype. The crucial difference is status, not just efficacy: tirzepatide is FDA-approved and widely prescribed, while CagriSema is not yet approved at all. For a head-to-head on the two approved leaders that defines the current standard CagriSema would have to beat, see our semaglutide versus tirzepatide comparison. The honest summary is that CagriSema looks competitive with the best available drugs, not obviously dominant over them, at least on the readouts so far.

Regulatory status: filed, under review, not yet approved

This is the part to be most careful about. Novo Nordisk has filed CagriSema with regulators and it is under review, but the FDA has not cleared CagriSema as of this writing. It is not an approved medication, and no clinician can legitimately prescribe it for weight management today. Anything sold online as "CagriSema" or as a "cagrilintide semaglutide" combination outside an approved channel is operating outside the regulated supply, which carries real safety risks around dosing and ingredient quality.

Filing a drug means the manufacturer has submitted its full data package and asked for approval. Review is the separate, later step where regulators assess that package and decide on approval, official dosing, and labeling. Positive phase 3 results do not guarantee a green light, and review timelines vary. So the accurate framing for CagriSema is "submitted and waiting," not "available." For the list of combinations and single agents that have actually crossed that line, our guide to FDA-approved GLP-1 medications is the reference to check against.

What CagriSema could mean for patients

If CagriSema clears review, its value is less about setting a new efficacy record and more about adding a genuinely different mechanism to the toolkit. Amylin is a distinct pathway from the GLP-1/GIP family, so a combination that recruits it could help people who respond only partially to existing drugs or who plateau on them. More effective options, and more mechanisms to choose from, is good for patients over time.

For now, the practical reality is unchanged. The drugs you can actually get are the approved ones, semaglutide and tirzepatide chief among them, available through a licensed clinician or a telehealth provider who can evaluate whether a GLP-1 therapy is appropriate and prescribe an approved medication if it is. The sensible approach is to make decisions based on what is approved today while keeping an eye on CagriSema's review, rather than waiting on a drug that has not yet been cleared or, worse, chasing an unregulated version of it. When CagriSema's status changes, a clinician already managing your care is the right person to discuss whether switching makes sense.

CagriSema is one of the more closely watched candidates in the obesity pipeline, and its review could reshape the options available within the next few years. If you want to act on what is proven and available today, the practical next step is a conversation with a licensed provider who can assess whether an approved GLP-1 medication fits your situation and arrange treatment if it does.